SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                ----------------

                                 SCHEDULE 13D
                    Under the Securities Exchange Act of 1934
                               (Amendment No. __)*


                          China Pharma Holdings, Inc.
--------------------------------------------------------------------------------
                                (Name of Issuer)


                    Common Stock, par value $0.001 per share
--------------------------------------------------------------------------------
                         (Title of Class of Securities)


                                   16941T104
--------------------------------------------------------------------------------
                                 (CUSIP Number)

                                    Zhilin Li
                                    President
                         2nd Floor, No. 17, Jinpan Road
                         Haikou, Hainan Province, China
                           Telephone: 86-898-6681 1730
--------------------------------------------------------------------------------
                 (Name, Address and Telephone Number of Person
               Authorized to Receive Notices and Communications)


                               September 13, 2006
--------------------------------------------------------------------------------
             (Date of Event which Requires Filing of This Statement)

If the filing person has previously  filed a statement on Schedule 13G to report
the  acquisition  that is the subject of this  Schedule  13D, and is filing this
schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box
[_].


Note:  Schedules  filed in paper format shall include a signed original and five
copies of the schedule, including all exhibits. See Rule 13d-7 for other parties
to whom copies are to be sent.


* The remainder of this cover page shall be filled out for a reporting  person's
initial filing on this form with respect to the subject class of securities, and
for  any  subsequent   amendment   containing   information  which  would  alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the  Securities  Exchange  Act of
1934 or  otherwise  subject to the  liabilities  of that  section of the Act but
shall be subject to all other provisions of the Act (however, see the Notes).






                              CUSIP No. 16941T104


________________________________________________________________________________
1    NAME OF REPORTING PERSONS
     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)


     Zhilin Li
________________________________________________________________________________
2    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
                                                                 (a)  [_]
                                                                 (b)  [X]

________________________________________________________________________________
3    SEC USE ONLY



________________________________________________________________________________
4    SOURCE OF FUNDS*


     OO
________________________________________________________________________________
5    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
     PURSUANT TO ITEMS 2(d) OR 2(e)                                   [_]



________________________________________________________________________________
6    CITIZENSHIP OR PLACE OF ORGANIZATION


     The People's Republic of China
________________________________________________________________________________
               7    SOLE VOTING POWER

  NUMBER OF
                    10,000,000 shares
   SHARES      _________________________________________________________________
               8    SHARED VOTING POWER
BENEFICIALLY

  OWNED BY          0
               _________________________________________________________________
    EACH       9    SOLE DISPOSITIVE POWER

  REPORTING
                    10,000,000 shares
   PERSON      _________________________________________________________________
               10   SHARED DISPOSITIVE POWER
    WITH

                    0
________________________________________________________________________________
11   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON


     10,000,000 shares
________________________________________________________________________________
12   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

                                                                      [_]

________________________________________________________________________________
13   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)


     28.8%
________________________________________________________________________________
14   TYPE OF REPORTING PERSON*


     IN
________________________________________________________________________________
                     *SEE INSTRUCTIONS BEFORE FILLING OUT!




Item 1.  Security and Issuer.

This  statement  relates to the common  stock,  par value  $0.001  (the  "Common
Stock") of China Pharma Holdings,  Inc., a Delaware corporation (the "Company").
The  Company's  principal  executive  offices are located at 2nd Floor,  No. 17,
Jinpan Road, Haikou, Hainan Province, China. 570216.


Item 2.  Identity and Background.

     (a)  This statement is filed by Zhilin Li ("Ms. Li" or "Reporting Person").

     (b)  The business  address of the  Reporting  Person is 2nd Floor,  No. 17,
          Jinpan Road, Haikou, Hainan Province, China. 570216;

     (c)  The Reporting Person is the director, president and CEO of the Issuer.
          She is also the  Chairman of the board of directors  and  president of
          Hainan Helpson Medicine and  Biotechnology  Co., Ltd, the wholly owned
          sub-subsidiary of the Issuer.

     (d)  Reporting  Person has not, during the last five years,  been convicted
          in a criminal  proceeding  (excluding  traffic  violations  or similar
          misdemeanors);

     (e)  The Reporting Person has not, during the last five years, been a party
          to a  civil  proceeding  of  a  judicial  or  administrative  body  of
          competent  jurisdiction  as a result of which was or is  subject  to a
          judgment,  decree or final order  enjoining  future  violations of, or
          prohibiting  or  mandating  activities  subject  to,  federal or state
          securities laws or finding any violation with respect to such laws;

     (f)  The Reporting Person is a citizen of the People's Republic of China


Item 3.  Source and Amount of Funds or Other Consideration.

Tsui  Heung  Mei  ("Tsui")   entered  into  a  Stock  Transfer   Agreement  (the
"Agreement")  with the  Reporting  Person  and the  Issuer  which was  closed on
September 13, 2006.  Pursuant to the Agreement,  the Reporting  Person  acquired
from Tsui 10,000,000 shares of common stock of the Company held by Tsui.


Item 4.  Purpose of Transaction.

The purpose of the  acquisition of the shares of common stock reported herein by
the Reporting Person was for investment.

     (a)  The Reporting Person has no present plans or proposals  relating to or
          that  would  result in the  acquisition  by any  person of  additional
          securities  of the issuer,  or the  disposition  of  securities of the
          issuer;

     (b)  The Reporting Person has no present plans or proposals  relating to or
          that would result in an extraordinary corporate transaction, such as a
          merger, reorganization or liquidation,  involving the issuer or any of
          its subsidiaries;

     (c)  The Reporting Person has no present plans or proposals  relating to or
          that would result in a sale or transfer of a material amount of assets
          of the issuer or any of its subsidiaries;





     (d)  On May 1,  2006,  the  Company  filed a Form 8-K (the  "Form  8-K") to
          disclose  that on May 1, 2006,  the Board of  Directors of the Company
          increased  the size of the Board from one to three and elected  Zhilin
          Li and Xinhua Wu as directors  to serve until the next annual  meeting
          of shareholders  and until their successors are elected and qualified.
          Furthermore,  on May 1,  2006,  the  Company  filed a  Certificate  of
          Amendment to its Articles of  Incorporation  ("the  Amendment") in the
          State of Delaware.  The Amendment  became  effective  immediately upon
          filing. The Amendment effected the following changes: 1) Change of the
          Company's  name from TS  Electronics,  Inc. to China Pharma  Holdings,
          Inc.; 2) Increase in the number of the Company's  authorized shares of
          common stock from Thirty Million  (30,000,000) shares to Sixty Million
          (60,000,000)   shares;   and  3)  Setting  the  number  of   directors
          constituting  the entire Board of Directors at between three and nine,
          with the  specific  number to be fixed  from time to time by a vote of
          the majority of the entire Board of Directors.

          The Form 8-K is incorporated herein by reference.  Except as described
          in the Form 8-K, the  Reporting  Person has no other  present plans or
          proposals  relating  to or that  would  result  in any  change  in the
          present Board of Directors or management of the Company, including any
          plans or  proposals  to change the number or term of  directors  or to
          fill any existing vacancies on the Board.

     (e)  The Company  filed an  amendment  to the  preliminary  Schedule 14C on
          March  15,  2006  (the  "14C  Amendment")  relating  to a  consent  of
          shareholders  dated  March  15,  2006 that  approved  1) Change of the
          Company's  name from TS  Electronics,  Inc. to China Pharma  Holdings,
          Inc.; 2) Increase in the number of the Company's  authorized shares of
          common stock from Thirty Million  (30,000,000) shares to Sixty Million
          (60,000,000)   shares;   and  3)  Setting  the  number  of   directors
          constituting  the entire Board of Directors at between three and nine,
          with the  specific  number to be fixed  from time to time by a vote of
          the majority of the entire Board of Directors. The Amendment is hereby
          incorporated  herein by  reference.  The  Company  filed a  definitive
          Schedule 14C on March 28, 2006 (the  "Definitive  Schedule  14C") with
          the same contents as the 14C Amendment. The Definitive Schedule 14C is
          hereby  incorporated  herein by reference.  Except as described in the
          14C Amendment and the  Definitive  Schedule 14C, the Reporting  Person
          has no present plans or proposals  relating to or that would result in
          a material change to the present  capitalization or dividend policy of
          the Company.

     (f)  Except as  described  in the Form 8-K,  the  Reporting  Person  has no
          present  plans or  proposals  relating to or that would  result in any
          other material change in the issuer's business or corporate  structure
          including but not limited to, if the issuer is a registered closed-end
          investment company,  any plans or proposals to make any changes in its
          investment  policy for which a vote is  required  by section 13 of the
          Investment Company Act of 1940.

     (g)  Except  as  described  in the  Form  8-K,  the 14C  Amendment  and the
          Definitive  Schedule 14C, the Reporting Person has no present plans or
          proposals  relating  to or that  would  result in any  changes  in the
          Company's charter,  by-laws, or instruments  corresponding  thereto or
          other  actions  which may  impede  the  acquisition  of control of the
          Company by any person.

     (h)  The Reporting Person has no present plans or proposals  relating to or
          that  would  result  in a class of  securities  of the  Company  being
          delisted  from a  national  securities  exchange  or to  ceasing to be
          authorized  to be  quoted  in an  inter-dealer  quotation  system of a
          registered national securities association.

     (i)  The Reporting Person has no present plans or proposals  relating to or
          that  would  result  in a class of  equity  securities  of the  issuer
          becoming eligible for termination of registration  pursuant to Section
          12(g)(4) of the Securities Exchange Act.

     (j)  The Reporting Person has no present plans or proposals  relating to or
          that  would  result in any action  similar to any of those  enumerated
          above.

Item 5.  Interest in Securities of the Issuer.

     (a)  The Reporting Person is the beneficial  owner of 10,000,000  shares of
          common  stock of the  Company.  The Company had  34,723,056  shares of
          common  stock  outstanding  as of September  14,  2006.  Based on that
          reported number of shares of common stock  outstanding,  The Reporting
          Person  has  beneficial   ownership  of  approximately  28.8%  of  the
          Company's outstanding common stock.

     (b)  The Reporting Person has sole power to vote or direct to vote and sole
          power to dispose or to direct the disposition of 10,000,000  shares of
          common stock.




     (c)  Reference  is  made to  Item  5(a)  above  for  information  regarding
          transactions  in  Company's  common  stock  effected by the  Reporting
          Person during the past 60 days.

     (d)  No other  person  has the right to  receive or the power to direct the
          receipt  of  dividends  from,  or the  proceeds  from the sale of such
          securities.

     (e)  Not applicable.


Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to
        Securities of the Issuer.

Other than as described  above,  to the best knowledge of the Reporting  Person,
there are no contracts, arrangements,  understandings or relationships (legal or
otherwise)  between  reporting  person  and  any  person  with  respect  to  any
securities of the issuer, including but not limited to transfer or voting of any
of the securities,  finder's fees, joint ventures,  loan or option  arrangements
puts or calls, guarantees of profits, division of profits or loss, or the giving
or  withholding  of  proxies,  naming  the , persons  with whom such  contracts,
arrangements understandin or relationship have been entered into.


Item 7.  Material to be Filed as Exhibits.

None.




















                                   SIGNATURE


     After  reasonable  inquiry and to the best of my  knowledge  and belief,  I
certify that the information  set forth in this statement is true,  complete and
correct.


September 21, 2006

By: /s/ Zhilin Li
   ----------------------------
   Zhilin Li, President and CEO